You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Lamivudine is indicated for the treatment of children (2 years and above), adolescent and adult patients with chronic hepatitis B and evidence of hepatitis B virus (HBV) replication.,This indication is based on changes in serological and histological markers in clinical studies of up to 2 years duration in adult patients with compensated liver disease and serological data up to 18 months in children and adolescents. Children and adolescents also require evidence of active hepatic inflammation. (see CLINICAL TRIALS).,The safety and efficacy of lamivudine 100 mg have not been established in patients with decompensated liver disease in placebo controlled studies. However, lamivudine 100 mg has been shown to reduce HBV DNA levels prior to and post liver transplantation.,The 100 mg tablet cannot meet dosage requirements in renal impairment in children 2-11 years and adults - see DOSAGE AND ADMINISTRATION. Oral solution dosage form can be available from other brand/s for patients whose body weight is less than 33 kg or patients for whom the tablets are inappropriate (See DOSAGE AND ADMINISTRATION).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Lamivudine is indicated for the treatment of children (2 years and above), adolescent and adult patients with chronic hepatitis B and evidence of hepatitis B virus (HBV) replication.,This indication is based on changes in serological and histological markers in clinical studies of up to 2 years duration in adult patients with compensated liver disease and serological data up to 18 months in children and adolescents. Children and adolescents also require evidence of active hepatic inflammation. (see CLINICAL TRIALS).,The safety and efficacy of lamivudine 100 mg have not been established in patients with decompensated liver disease in placebo controlled studies. However, lamivudine 100 mg has been shown to reduce HBV DNA levels prior to and post liver transplantation.,The 100 mg tablet cannot meet dosage requirements in renal impairment in children 2-11 years and adults - see DOSAGE AND ADMINISTRATION. Oral solution dosage form can be available from other brand/s for patients whose body weight is less than 33 kg or patients for whom the tablets are inappropriate (See DOSAGE AND ADMINISTRATION).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Lamivudine is indicated for the treatment of children (2 years and above), adolescent and adult patients with chronic hepatitis B and evidence of hepatitis B virus (HBV) replication.,This indication is based on changes in serological and histological markers in clinical studies of up to 2 years duration in adult patients with compensated liver disease and serological data up to 18 months in children and adolescents. Children and adolescents also require evidence of active hepatic inflammation. (see CLINICAL TRIALS).,The safety and efficacy of lamivudine 100 mg have not been established in patients with decompensated liver disease in placebo controlled studies. However, lamivudine 100 mg has been shown to reduce HBV DNA levels prior to and post liver transplantation.,The 100 mg tablet cannot meet dosage requirements in renal impairment in children 2-11 years and adults - see DOSAGE AND ADMINISTRATION. Oral solution dosage form can be available from other brand/s for patients whose body weight is less than 33 kg or patients for whom the tablets are inappropriate (See DOSAGE AND ADMINISTRATION).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Lamivudine is indicated for the treatment of children (2 years and above), adolescent and adult patients with chronic hepatitis B and evidence of hepatitis B virus (HBV) replication.,This indication is based on changes in serological and histological markers in clinical studies of up to 2 years duration in adult patients with compensated liver disease and serological data up to 18 months in children and adolescents. Children and adolescents also require evidence of active hepatic inflammation. (see CLINICAL TRIALS).,The safety and efficacy of lamivudine 100 mg have not been established in patients with decompensated liver disease in placebo controlled studies. However, lamivudine 100 mg has been shown to reduce HBV DNA levels prior to and post liver transplantation.,The 100 mg tablet cannot meet dosage requirements in renal impairment in children 2-11 years and adults - see DOSAGE AND ADMINISTRATION. Oral solution dosage form can be available from other brand/s for patients whose body weight is less than 33 kg or patients for whom the tablets are inappropriate (See DOSAGE AND ADMINISTRATION).
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
